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Poster Session II S307Conclusions: Progressive improvement in cutaneous manifestations
of cGVHD was observed following a 24-week course of ECP in pts
who previously had exhibited no clinical response or worsening of
cGVHD while receiving standard immunosuppressive therapy
with corticosteroids. ECP improved skin GVHD and allowed for ta-
pering of corticosteroid doses to ‘‘low risk’’ levels of\10 mg predni-
sone-equivalents/day.406
NON-HEMATOPOIETIC ANTIGEN BLOCKS EARLY MEMORY IMPRINTING
OF GRAFT-VERSUS-HOST REACTIVE CD8 CELLS
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Donor T cell alloreactivity can be co-opted to deliver a graft-versus-
tumor (GVT) response following blood or bone marrow transplanta-
tion (BMT). However, the major reason for treatment failure
following BMT is tumor recurrence, suggesting a long-term failure
of GVT immunity. In this study, we have considered the role of
non-hematopoietic antigen in determining the fate of donor CD8 cells
in a model of delayed DLI to partially MHC-mismatched chimeras,
where antigen was either expressed ubiquitously or restricted to the
hematopoietic compartment. We observed that donor CD8 cytotoxic
and cytokine responses were poorly sustained (at .8 weeks) in the
presence of non-hematopoietic antigen and this was associated with
a failure to establish a central memory (TCM) population. This effect
occurred at two distinct levels. Firstly, residual donor CD8 cells dem-
onstrated a classic PD-1highCD127low ‘exhaustion’ signature and con-
sistent with this, CD8 functions were partially restored by blockade of
the PD-1 pathway. Secondly, during the initial phase of the primary
response (at day 5-8 following transfer of CFSE-labelled splenocytes),
we observed that the proportion of post-mitotic, CFSElow CD8 cells
expressing a CD44highCD62Lhigh phenotype was much lower in chi-
meras where antigen was ubiquitous. These findings suggested the
possibility that early CD8 encounter with non-hematopoietic antigen
might severely disable memory precursor formation during the initial
phase of the response. In order to test this concept, we purified CD8 T
cells using congenic markers from the two sets of chimeras 14 days af-
ter initial T cell transfer, and then parked them in secondary, antigen
free hosts. After 21 days, we tested recall responses to alloantigen. We
found that priming in the presence of non-hematopoietic antigen se-
verely impaired the establishment of recall immunity in the absence of
antigen. Furthermore, while a significant proportion of CD8 T cells
primed in the absence of non-hematopoietic antigen had a (TCM) phe-
notype in secondary hosts, this population was almost entirely absent
when initial priming occurred in primary hosts where antigen was
ubiquitous. These data demonstrate that alloantigen within non-he-
matopoietic tissues is not ignored, but rather actively inhibits both
the formation and maintenance of CD8 T cell memory. While these
effects may lessen the risk of GVHD, they might also impair the dura-
bility of the GVT response.407
TRAIL/DR5 INTERACTIONS ARE IMPORTANT FOR MEDIATING THYMIC
DAMAGE AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION
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Thymic GVHD (tGVHD) is associated with prolonged immuno-
deficiency. We previously found that thymic output after allo-BMT
is directly related to thymus size, and inversely related to donor T
cell dose and GVHD severity. Additionally, radiation-containing
preparative regimens upregulate the death receptors Fas and DR5
on thymic stroma and decrease expression of cFLIP, thus sensitizing
the thymus to GVHD. Finally, very few donor alloreactive T cellsare sufficient to cause tGVHD via the Fas/Fas ligand (FasL) and
TRAIL/DR5 pathways.
Here, we performed allo-BMT in MHC-mismatched and
MHC-matched minor antigen-disparate model systems, and dem-
onstrated the exquisite sensitivity of the thymus to as few as
1-2.5105 donor T cells, which mediated tGVHD without sig-
nificant clinical GVHD. Additionally, tGVHD is partially revers-
ible in our models (contingent on low T cell dose), such that
mice with tGVHD exhibit a partial recovery in thymic cellularity
late (day 60) post-transplant.
We further studied the role of TRAIL in tGVHD, by asking
whether alloreactive T cells and GVHD or conditioning-associated
inflammation were strictly required for TRAIL/DR5-mediated
damage. We treated recipients of T cell-depleted allo-BMT with
mDR5-1 agonistic antibody either in the ‘‘early’’ peri-transplant pe-
riod, or ‘‘late,’’ in the second week post-transplant.
Allo-BMT recipients treated ‘‘early’’ with mDR5-1 had signifi-
cantly decreased thymic cellularity and splenic BM-derived T cells
as compared with controls. Furthermore, we observed similar BM cel-
lularity and BM-derived lineage- sca-1+ckit+ (LSK), all in the absence
of donor alloreactive T cells or GVHD. We observed similar results
with mice treated with ‘‘late’’ mDR5-1, indicating the continued sen-
sitivity of the thymus to TRAIL throughout the post-transplant pe-
riod, and that GVHD and/or conditioning-associated cytokines are
not required to enable TRAIL-mediated damage to the thymus.
Furthermore, we observed that on day 28 after T cell-depleted
allo-BMT, only 1-2% of donor thymocytes expressed DR5, suggest-
ing that mDR5-1 (and potentially TRAIL) mediate their effects on
thymic cellularity and function primarily via an indirect mechanism.
We conclude that the thymus is highly sensitive to GVHD and en-
dures severe damage at low levels of systemic GVHD. Furthermore,
we provide significant additional mechanistic insight into the tempo-
ral, cellular, and inflammatory requirements for TRAIL/DR5 medi-
ated damage to the thymus.408
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P-selectin is found on most inflamed endothelium and interacts
with multiple leukocyte ligands. We found that P selectin-/- recipi-
ents of allogeneic bone marrow transplantation (allo-BMT) had sig-
nificantly less GVHD mortality and morbidity, as well as decreased
GVHD of the skin, liver and small bowels. This was associated with
diminished infiltration of alloactivated T cells into the Peyer’s
Patches and small bowels, coupled with increased numbers of donor
T cells in the spleen and secondary lymphoid organs (SLO) on day
14 and day 35 post-transplant. However, donor alloreactive T cells
in WT and P-selectin-/- allo-BMT recipients had similar alloactiva-
tion and apoptosis, and donor alloactivated T cells from WT and
P-selectin-/- allo-BMT recipients with GVHD showed similar pro-
liferation in vitro in a mixed leukocyte reaction, suggesting that the
inflammatory environment in WT and P-selectin-/- recipients was
comparable.
P-selectin glycoprotein ligand 1 (PSGL1) is the best-described
P-selectin ligand, and we then tested the role of PSGL1-/- donor al-
loreactive T cells in mediating GVHD. To our surprise, allo-BMT
recipients of WT and PSGL1-/- donor T cells had comparable sur-
vival and clinical GVHD scores, and further analyses on day 14 post-
transplant revealed similar numbers of donor alloactivated T cells in
the spleen, liver, mesenteric and peripheral lymph nodes, and Peyer’s
Patches. Additionally, WT and PSGL1-/- donor T cells had compa-
rable proliferation as measured by CFSE dilution, and comparable
alloactivation in vivo as determined by levels of CD25, CD44, and
CD62L.
We then asked whether PSGL1-/- T cells might display other P-se-
lectin ligands. Flow cytometric analyses of T cells from non-trans-
planted PSGL1-/- mice, and analyses of PSGL1-/- alloactivated T
S308 Poster Session IIcells on day 14 after allo-BMT, revealed that these cells displayed sub-
stantial levels of cell-surface P-selectin ligands as defined by positive
staining with recombinant P-selectin-IgG-Fc fusion protein at levels
similar to those foundon WT T cells, suggesting that althoughabsence
of P-selectin on host tissues may ameliorate GVHD, multiple donor
leukocyte P-selectin ligands interact meaningfully with P-selectin.
Our studies suggest that P-selectin may be required for trafficking
into inflamed tissues but not SLO, and that donor T cells may utilize
multiple P-selectin ligands apart from PSGL1 to interact with P-se-
lectin and traffic into inflamed tissues during GVHD.409
PATTERNS OF CHRONIC GRAFT-VS-HOST DISEASE AND ASSOCIATED
MORTALITY AFTER MYELOABLATIVE CONDITIONING INCORPORATING
FLUDARABINE, BUSULFAN AND ATG
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Preparative regimens incorporating antithymocyte globulin
(ATG) have been shown to decrease the incidence of both acute
and chronic graft-versus-host disease (aGVHD and cGVHD). It is
less clear whether prior ATG influences the pattern of onset, duration
of treatment and graft-versus-malignancy(GVM) effect of cGVHD.
Between 1999 and 2008, 538 patients (pts) with hematologic malig-
nancy aged 18–66 years (median 46) received blood cell (n5 440,
82%) or marrow transplants after conditioning with Flu 50 mg/m2
daily  5 and IV Bu 3.2 mg/kg daily  4. Two hundred and thirty-
four (43%) had additional total body irradiation (TBI) 200 cGy 2.
GVHD prophylaxis was cyclosporin A, methotrexate and Thymo-
globulin (Genzyme) 4.5 mg/kg total dose. Donors were matched sib-
lings in 299 (56%), mismatched related in 27(5%), 10/10 matched
unrelated in 146 (27%) and mismatched unrelated in 66(12%).
Two hundred and fifty-six pts (48%) had low-risk (LR, acute leuke-
mia CR1/CR2, CML CP1) disease. Incidence of aGVHD grade II-
IV, aGVHD grade III-IV and cGVHD (at 2 years) was 24%, 10%
and 56% respectively. Of 474 pts surviving .100days, 371 (78%)
had no or grade I aGVHD, 167 (45%) of whom developed cGVHD.
Of the 103 pts with prior grade II-IV aGVHD, 4 died before d126 of
late effects of aGVHD (and are excluded from the analysis of the no
cGVHD group), 17 survived without cGVHD, 21 developed
cGVHD after discontinuing treatment for aGVHD (‘‘quiescent’’
cGVHD) of whom 2 (10%) died without relapse. Sixty-one devel-
oped cGVHD before completing treatment for aGVHD grade II-
IV, defined as ‘‘progressive’’ cGVHD (pcGVHD) for the purpose
of this study. There were therefore 188 pts with ‘‘non-progressive’’
cGVHD (npcGVHD) (167 de novo plus 21 ‘‘quiescent’’) and 221
with no cGVHD. At follow-up of survivors of 14–124 months (me-
dian 60) 5 year outcomes (%) were as follows:(see table).
All pcGVHD pts and 143 npcGVHD pts (76%) required systemic
therapy. Median time on treatment was 495 days compared with 286
days (p5 0.07), with 79% and 83% respectively being off immuno-
suppression by 3 years from onset of cGVHD. Despite a relatively
low incidence of aGVHD with this regimen about 60% of those
who do develop grade II-IV aGVHD and live100 days develop
pcGVHD with a significantly higher risk of NRM than other pts. Be-
cause of less relapse and equivalent NRM, OS and DFS are better in
pts with npcGVHD than those with no cGVHD. The challenge re-
mains to prevent aGVHD without sacrificing the GVM effect of
cGVHD.5 years outcomes in relation to cGVHD
npcGVHD(%) No cGVHD(%) pcGVHD(%) p value
OS 68*† 61* 50† *0.02, † 0.006
DFS 66*† 55* 42† *0.003,† 0.004
NRM 8* 12† 42*† *†\0.0001
Relapse 28* 39*† 28† *0.006, †0.02410
FLUTICASONE, AZITHROMYCIN, AND MONTELUKAST (FAM) THERAPY IN
REDUCING STEROID EXPOSURE IN BRONCHIOLITIS OBLITERANS SYN-
DROME AFTER ALLOGENEIC HEMATOPOETIC STEM CELL TRANSPLANT
(HCT)– A CASE SERIES OF 8 PATIENTS
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Background: Bronchiolitis obliterans syndrome (BOS) is a rare and
serious complication of allogeneic HCT, requiring long courses of
systemic corticosteroids that are often associated with adverse conse-
quences. Thus, novel therapies to reduce corticosteroid exposure
may be beneficial.
Hypothesis: Combined treatment with fluticasone, azithromycin
and montelukast (FAM), three agents with anti-inflammatory and
antifibrotic properties, all with low toxicity, will reduce the overall
six-month exposure to corticosteroids in BOS patients.
Methods: Between June 2008 and the present, we reviewed 8 pa-
tients who met NIH criteria for newly diagnosed BOS and were
treated with FAM therapy indefinitely and a 2-week pulse of high
dose (1 mg/kg/day) prednisone followed by a rapid taper. These
patients were compared with 14 historical controls identified
from a pre-existing database, who also met NIH criteria, and re-
ceived high dose prednisone therapy followed by a standard taper.
The total prednisone exposure (median values and interquartile
ranges) six months after diagnosis and interval change in FEV1 at
three, and/or six months after BOS diagnosis were compared.
FEV1 was reported as percent predicted with preference given to
post-bronchodilator values. FEV1 change was defined as change
in FEV1 from diagnosis to three or six months, depending on
pulmonary function test availability. Treatment failure was defined
as a decline in FEV1$ 10% and clinical worsening of symptoms
resulting in increase in prednisone dose within six months of
diagnosis.
Results: The median six month prednisone exposure for the FAM-
treated patients was 1819 mg [25th percentile5 0 mg; 75th percenti-
le5 4036 mg] compared to 7163 mg [25th percentile5 6551 mg;
75th percentile5 7829 mg] in the control group. The median
FEV1 change in the FAM group was 2% [25
th percentile5 -7%;
75th percentile5 4%] compared to 1% [25th percentile5 -4%;
75th percentile5 5%] in the control group. There was one treatment
failure in the FAM group (12%) compared to one in the control
group (7%).
Conclusions:The total six month prednisone exposure in a group of
eight patients treated with FAM therapy was one quarter that of a ret-
rospective group of BOS patients who were treated with standard
prednisone therapy, with minimal change in median FEV1 in both
groups. FAM therapy may allow for less total exposure to corticoste-
roids and may avert some complications associated with steroid
therapy.411
PATIENTS WITH CUTANEOUS GRAFT VERSUS HOST DISEASE EXHIBIT
REDUCED PRODUCTION OF IL-17
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It is well recognized that T cells are the principal orchestrators
of graft versus host disease (GVHD). Historically, IFN-g produc-
ing Th1 cells have been implicated in the pathogenesis of acute
GVHD (aGVHD) whereas Th2 cells have been thought to be in-
volved in the pathogenesis of chronic GVHD (cGVHD). The re-
cent discovery of a distinct lineage of IL-17 producing Th17
cells, thought to be the major perpetrators in a number of inflam-
matory and autoimmune disorders, has prompted re-evaluation of
the Th1/Th2 paradigm of GVHD. Studies in IL-17 deficient
mice have shown conflicting results with IL-17 having both a pro-
tective or deleterious effect, whereas transplantation of purified
Th17 cells causes GVHD-related tissue damage with a predilection
for the skin and lungs. In this study we aimed to determine whether
Th17 cells play a role in the pathogenesis of human GVHD. 37
